New and Emerging Strategies in the Treatment of High-Risk MDS Patients

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: November 16, 2016
Expiration Date: November 16, 2017

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

The treatment and management of patients with high-risk myelodysplastic syndromes (MDS) is challenging, owing in part to the complexities of risk-stratification, as well as limited available treatment options. In this activity, Dr. David Steensma, an Associate Professor of Medicine at Harvard Medical School, describes the appropriate identification of higher-risk MDS based on the revised International Prognostic Scoring System (IPSS-R) and recent data regarding the impact of cytogenetics on existing risk-stratification strategies. In addition, Dr. Steensma provides an overview of the treatment landscape in higher-risk MDS, including data to support existing treatment options and new therapies currently being investigated in clinical trials.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in treatment strategies for high-risk MDS patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify high-risk patients with MDS and correlate risk with disease prognosis and survival
  • Summarize the efficacy and safety of therapies for patients with high-risk MDS, including growth factors, demethylating agents, and IMiDs
  • Identify therapies under investigation in clinical trials for high-risk MDS


New and Emerging Strategies in the Treatment of High-Risk MDS Patients – David P. Steensma, MD, FACP

Instructions for Participation and Credit

This activity is eligible for credit through November 16, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

David Steensma, MD, FACP
Assistant Professor of Medicine
Harvard Medical School
Senior Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. David Steensma received his medical degree from the University of Chicago’s Pritzker School of Medicine. He completed an internal medicine residency and a combined hematology-oncology fellowship at the Mayo Clinic in Rochester, Minnesota. He is Associate Professor of Medicine at Harvard Medical School and Senior Physician in the Division of Hematological Malignancies at Dana-Farber Cancer Institute in Boston, Massachusetts. In addition, Dr. Steensma is a consulting physician at Brigham & Women’s Hospital.

Following completion of his formal training, Dr. Steensma spent several years as a visiting research scholar in the Molecular Haematology Unit of the Weatherall Institute of Molecular Medicine, University of Oxford, England, investigating the molecular genetics of myelodysplastic syndromes. He is board certified by the American Board of Internal Medicine in internal medicine, hematology, and medical oncology. Dr. Steensma has published more than 250 peer-reviewed papers, served as editor for several American Society of Hematology (ASH) publications, is education co-chair for the ASH Annual Meeting, section editor for the Journal of Clinical Oncology, and on the hematology committee of the American Board of Internal Medicine.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-111-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. David Steensma has received honoraria as a consultant from Celgene Corporation, Genoptix–a Novartis Company, H3, Incyte Corporation, and Seattle Genetics, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Physician Payments, Sunshine Act

MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.